William Blair Issues Negative Estimate for ARCT Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Analysts at William Blair decreased their Q1 2025 earnings estimates for shares of Arcturus Therapeutics in a report issued on Thursday, March 13th. William Blair analyst M. Minter now expects that the biotechnology company will post earnings per share of ($1.39) for the quarter, down from their previous estimate of ($0.53). The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.22) per share. William Blair also issued estimates for Arcturus Therapeutics’ Q2 2025 earnings at ($1.41) EPS, Q3 2025 earnings at ($1.15) EPS, Q4 2025 earnings at ($1.36) EPS, FY2025 earnings at ($5.31) EPS, Q1 2026 earnings at ($1.39) EPS, Q2 2026 earnings at ($1.48) EPS, Q3 2026 earnings at ($1.52) EPS, Q4 2026 earnings at ($1.59) EPS, FY2026 earnings at ($5.98) EPS and FY2027 earnings at $0.41 EPS.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $22.77 million for the quarter, compared to analysts’ expectations of $44.64 million.

ARCT has been the subject of a number of other reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. BTIG Research set a $48.00 price objective on shares of Arcturus Therapeutics and gave the company a “buy” rating in a research note on Monday, March 10th. HC Wainwright reduced their price target on shares of Arcturus Therapeutics from $63.00 to $60.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Canaccord Genuity Group reduced their price target on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, March 10th. Finally, Wells Fargo & Company reduced their price target on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $59.20.

Arcturus Therapeutics Trading Down 3.0 %

ARCT stock opened at $13.73 on Monday. Arcturus Therapeutics has a one year low of $12.75 and a one year high of $45.00. The firm has a market capitalization of $372.36 million, a PE ratio of -6.18 and a beta of 2.96. The firm has a 50-day moving average of $16.40 and a two-hundred day moving average of $18.19.

Institutional Trading of Arcturus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ARCT. Virtus ETF Advisers LLC lifted its stake in Arcturus Therapeutics by 38.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 1,132 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Arcturus Therapeutics in the fourth quarter valued at approximately $71,000. National Bank of Canada FI lifted its stake in Arcturus Therapeutics by 639.6% in the fourth quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company’s stock valued at $94,000 after acquiring an additional 4,784 shares during the last quarter. Kennedy Capital Management LLC lifted its stake in Arcturus Therapeutics by 22.7% in the fourth quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 2,036 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC acquired a new stake in Arcturus Therapeutics in the fourth quarter valued at approximately $200,000. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.